Differences in the expression of SSTR1-5 in meningiomas and its therapeutic potential.
Immunohistochemistry
Meningioma
Neurofibromatosis
Peptide receptor radionuclide therapy (PRRT)
Somatostatin receptor
Tissue microarray
Journal
Neurosurgical review
ISSN: 1437-2320
Titre abrégé: Neurosurg Rev
Pays: Germany
ID NLM: 7908181
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
03
03
2021
accepted:
15
04
2021
revised:
03
04
2021
pubmed:
27
4
2021
medline:
12
2
2022
entrez:
26
4
2021
Statut:
ppublish
Résumé
Beyond microsurgical resection and radiation therapy, there are currently no established treatment alternatives for meningioma patients. In selected cases, peptide radio receptor therapy (PRRT) can be implemented. For this purpose, a radionuclide is bound to a substance targeting specific receptors in meningiomas. One of them is somatostatin receptor 2, which can be found in most meningiomas. However, other somatostatin receptors (SSTR) exist, but their expressions have only been described in small case series. In this study, we analyzed the expression of SSTR1, 2A, 3, 4, and 5 in a large cohort of meningiomas in order to enable further refinement of this innovative treatment option. Overall, 726 tumor samples were processed into tissue microarrays and stained for SSTR1, 2A, 3, 4, and 5 immunohistochemically. Microscopic evaluation was done with an established semiquantitative score regarding percentual quantification and staining intensity, and results were correlated with clinical data. There was a significant lower rate of SSTR1 expression in meningiomas of male patients. Older age was associated with higher expression of SSTR1, 2A, and 5 and lower scores for SSTR3 and 4. Tumors treated with radiotherapy before resection showed lower rates of SSTR1 and 5 expression, while recurrent meningiomas had lower SSTR1 scores. Tumor tissue from patients suffering from neurofibromatosis type 2 had lower expression scores for SSTR1, 2, and 5. For SSTR3 and 4, NF2 patients showed higher scores than sporadic tumors. Spinal meningiomas had higher scores for SSTR1, 4, and 5 compared tumor location of the skull base and convexity/falx. Overall, higher WHO grade was associated with lower SSTR scores. While all SSTRs were expressed, there are marked differences of SSTR expression between meningioma subgroups. This has the potential to drive the development of more selective PRRT substances with higher treatment efficacy.
Identifiants
pubmed: 33899156
doi: 10.1007/s10143-021-01552-y
pii: 10.1007/s10143-021-01552-y
pmc: PMC8827401
doi:
Substances chimiques
Receptors, Somatostatin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
467-478Informations de copyright
© 2021. The Author(s).
Références
Ardern-Holmes S, Fisher G, North K (2017) Neurofibromatosis Type 2. J Child Neurol 32:9–22. https://doi.org/10.1177/0883073816666736
doi: 10.1177/0883073816666736
pubmed: 27655473
Arena S, Barbieri F, Thellung S, Pirani P, Corsaro A, Villa V, Dadati P, Dorcaratto A, Lapertosa G, Ravetti JL, Spaziante R, Schettini G, Florio T (2004) Expression of somatostatin receptor mRNA in human meningiomas and their implication in in vitro antiproliferative activity. J Neurooncol 66:155–166. https://doi.org/10.1023/b:neon.0000013498.19981.55
doi: 10.1023/b:neon.0000013498.19981.55
pubmed: 15015781
Barresi V, Alafaci C, Salpietro F, Tuccari G (2008) Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density? Oncol Rep 20:485–492
pubmed: 18695896
Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E, Baio SM, Arico D, Sansovini M, Paganelli G (2009) Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging 36:1407–1416. https://doi.org/10.1007/s00259-009-1115-z
doi: 10.1007/s00259-009-1115-z
pubmed: 19319527
Brastianos PK, Galanis E, Butowski N, Chan JW, Dunn IF, Goldbrunner R, Herold-Mende C, Ippen FM, Mawrin C, McDermott MW, Sloan A, Snyder J, Tabatabai G, Tatagiba M, Tonn JC, Wen PY, Aldape K, Nassiri F, Zadeh G, Jenkinson MD, Raleigh DR, International Consortium on M (2019) Advances in multidisciplinary therapy for meningiomas. Neuro Oncol 21:i18–i31. https://doi.org/10.1093/neuonc/noy136
doi: 10.1093/neuonc/noy136
pubmed: 30649489
pmcid: 6347080
Buglione M, De Bari B, Trevisan F, Ghirardelli P, Pedretti S, Triggiani L, Magrini SM (2014) Role of external beam radiotherapy in the treatment of relapsing meningioma. Med Oncol 31:866. https://doi.org/10.1007/s12032-014-0866-y
doi: 10.1007/s12032-014-0866-y
pubmed: 24504843
Chamberlain MC, Glantz MJ, Fadul CE (2007) Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 69:969–973. https://doi.org/10.1212/01.wnl.0000271382.62776.b7
doi: 10.1212/01.wnl.0000271382.62776.b7
pubmed: 17785665
Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, Avsar T, Li J, Murray PB, Henegariu O, Yilmaz S, Gunel JM, Carrion-Grant G, Yilmaz B, Grady C, Tanrikulu B, Bakircioglu M, Kaymakcalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra-Gorur K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilguvar K, Baehring JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kilic T, Lifton RP, Noonan JP, Yasuno K, Gunel M (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339:1077–1080. https://doi.org/10.1126/science.1233009
doi: 10.1126/science.1233009
pubmed: 23348505
pmcid: 4808587
Dash A, Chakraborty S, Pillai MR, Knapp FF Jr (2015) Peptide receptor radionuclide therapy: an overview. Cancer Biother Radiopharm 30:47–71. https://doi.org/10.1089/cbr.2014.1741
doi: 10.1089/cbr.2014.1741
pubmed: 25710506
Dressen MS, Muthukrishnan A, Tragon TR, Lieberman FS, Mountz JM (2019) Complementary molecular and metabolic characterization of meningiomas with DOTATATE and FDG-PET: advancing treatment planning and prognostication. Clin Nucl Med 44:e26–e27. https://doi.org/10.1097/RLU.0000000000002328
doi: 10.1097/RLU.0000000000002328
pubmed: 30371576
Dutour A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R, Patel YC (1998) Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer 76:620–627
Froidevaux S, Eberle AN (2002) Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 66:161–183. https://doi.org/10.1002/bip.10256
doi: 10.1002/bip.10256
pubmed: 12385036
Gerster-Gillieron K, Forrer F, Maecke H, Mueller-Brand J, Merlo A, Cordier D (2015) 90Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas. J Nucl Med 56:1748–1751. https://doi.org/10.2967/jnumed.115.155853
doi: 10.2967/jnumed.115.155853
pubmed: 26294303
Gilard V, Goia A, Ferracci FX, Marguet F, Magne N, Langlois O, Perez A, Derrey S (2018) Spinal meningioma and factors predictive of post-operative deterioration. J Neurooncol 140:49–54. https://doi.org/10.1007/s11060-018-2929-y
doi: 10.1007/s11060-018-2929-y
pubmed: 29926318
Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, von Deimling A, Stavrinou P, Lefranc F, Lund-Johansen M, Moyal EC, Brandsma D, Henriksson R, Soffietti R, Weller M (2016) EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol 17:e383-391. https://doi.org/10.1016/S1470-2045(16)30321-7
doi: 10.1016/S1470-2045(16)30321-7
pubmed: 27599143
Graillon T, Romano D, Defilles C, Lisbonis C, Saveanu A, Figarella-Branger D, Roche PH, Fuentes S, Chinot O, Dufour H, Barlier A (2017) Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro. Oncotarget 8:55361–55373. https://doi.org/10.18632/oncotarget.19517
doi: 10.18632/oncotarget.19517
pubmed: 28903425
pmcid: 5589664
Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyriere H, Basset N, Autran D, Roche C, Kalamarides M, Roche PH, Fuentes S, Tabouret E, Barrie M, Cohen A, Honore S, Boucekine M, Baumstarck K, Figarella-Branger D, Barlier A, Dufour H, Chinot OL (2020) Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trial. Clin Cancer Res 26:552–557. https://doi.org/10.1158/1078-0432.CCR-19-2109
doi: 10.1158/1078-0432.CCR-19-2109
pubmed: 31969329
Hanscheid H, Sweeney RA, Flentje M, Buck AK, Lohr M, Samnick S, Kreissl M, Verburg FA (2012) PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma. Eur J Nucl Med Mol Imaging 39:1284–1288. https://doi.org/10.1007/s00259-012-2124-x
doi: 10.1007/s00259-012-2124-x
pubmed: 22526964
Hartrampf PE, Hanscheid H, Kertels O, Schirbel A, Kreissl MC, Flentje M, Sweeney RA, Buck AK, Polat B, Lapa C (2020) Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Clin Transl Radiat Oncol 22:29–32. https://doi.org/10.1016/j.ctro.2020.03.002
doi: 10.1016/j.ctro.2020.03.002
pubmed: 32195377
pmcid: 7075763
Hsu DW, Efird JT, Hedley-Whyte ET (1997) Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 86:113–120. https://doi.org/10.3171/jns.1997.86.1.0113
doi: 10.3171/jns.1997.86.1.0113
pubmed: 8988089
Karsy M, Guan J, Cohen A, Colman H, Jensen RL (2016) Medical management of meningiomas: current status, failed treatments, and promising horizons. Neurosurg Clin N Am 27:249–260. https://doi.org/10.1016/j.nec.2015.11.002
doi: 10.1016/j.nec.2015.11.002
pubmed: 27012389
Konstantinidou AE, Korkolopoulou P, Mahera H, Kotsiakis X, Hranioti S, Eftychiadis C, Patsouris E (2003) Hormone receptors in non-malignant meningiomas correlate with apoptosis, cell proliferation and recurrence-free survival. Histopathology 43:280–290. https://doi.org/10.1046/j.1365-2559.2003.01712.x
doi: 10.1046/j.1365-2559.2003.01712.x
pubmed: 12940781
Kreissl MC, Hanscheid H, Lohr M, Verburg FA, Schiller M, Lassmann M, Reiners C, Samnick SS, Buck AK, Flentje M, Sweeney RA (2012) Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiat Oncol 7:99. https://doi.org/10.1186/1748-717X-7-99
doi: 10.1186/1748-717X-7-99
pubmed: 22720902
pmcid: 3439242
Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124–2130. https://doi.org/10.1200/JCO.2007.15.2553
doi: 10.1200/JCO.2007.15.2553
pubmed: 18445841
Lamberts SW, Krenning EP, Reubi JC (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12:450–482. https://doi.org/10.1210/edrv-12-4-450
doi: 10.1210/edrv-12-4-450
pubmed: 1684746
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1
doi: 10.1007/s00401-016-1545-1
pubmed: 27157931
Minutoli F, Amato E, Sindoni A, Cardile D, Conti A, Herberg A, Baldari S (2014) Peptide receptor radionuclide therapy in patients with inoperable meningiomas: our experience and review of the literature. Cancer Biother Radiopharm 29:193–199. https://doi.org/10.1089/cbr.2013.1599
doi: 10.1089/cbr.2013.1599
pubmed: 24811687
Oberg K, Lamberts SW (2016) Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocr Relat Cancer 23:R551–R566. https://doi.org/10.1530/ERC-16-0151
doi: 10.1530/ERC-16-0151
pubmed: 27697899
Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS (2019) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol 21:v1–v100. https://doi.org/10.1093/neuonc/noz150
doi: 10.1093/neuonc/noz150
pubmed: 31675094
pmcid: 6823730
Reubi JC (2004) Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 80(Suppl 1):51–56. https://doi.org/10.1159/000080742
doi: 10.1159/000080742
pubmed: 15477718
Reubi JC, Laissue JA (1995) Multiple actions of somatostatin in neoplastic disease. Trends Pharmacol Sci 16:110–115. https://doi.org/10.1016/s0165-6147(00)88992-0
doi: 10.1016/s0165-6147(00)88992-0
pubmed: 7792931
Reubi JC, Kappeler A, Waser B, Laissue J, Hipkin RW, Schonbrunn A (1998) Immunohistochemical localization of somatostatin receptors sst2A in human tumors. Am J Pathol 153:233–245. https://doi.org/10.1016/S0002-9440(10)65564-2
doi: 10.1016/S0002-9440(10)65564-2
pubmed: 9665484
pmcid: 1852945
Reuss DE, Piro RM, Jones DT, Simon M, Ketter R, Kool M, Becker A, Sahm F, Pusch S, Meyer J, Hagenlocher C, Schweizer L, Capper D, Kickingereder P, Mucha J, Koelsche C, Jager N, Santarius T, Tarpey PS, Stephens PJ, Andrew Futreal P, Wellenreuther R, Kraus J, Lenartz D, Herold-Mende C, Hartmann C, Mawrin C, Giese N, Eils R, Collins VP, Konig R, Wiestler OD, Pfister SM, von Deimling A (2013) Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol 125:351–358. https://doi.org/10.1007/s00401-013-1093-x
doi: 10.1007/s00401-013-1093-x
pubmed: 23404370
Ribatti D, Conconi MT, Nussdorfer GG (2007) Nonclassic endogenous novel [corrected] regulators of angiogenesis. Pharmacol Rev 59:185–205. https://doi.org/10.1124/pr.59.2.3
doi: 10.1124/pr.59.2.3
pubmed: 17540906
Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, Schiff D, Weber DC, Wen PY, Vogelbaum MA (2015) Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 122:4–23. https://doi.org/10.3171/2014.7.JNS131644
doi: 10.3171/2014.7.JNS131644
pubmed: 25343186
pmcid: 5062955
Schulz S, Pauli SU, Schulz S, Handel M, Dietzmann K, Firsching R, Hollt V (2000) Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res 6:1865–1874
pubmed: 10815909
Seystahl K, Stoecklein V, Schuller U, Rushing E, Nicolas G, Schafer N, Ilhan H, Pangalu A, Weller M, Tonn JC, Sommerauer M, Albert NL (2016) Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. Neuro Oncol 18:1538–1547. https://doi.org/10.1093/neuonc/now060
doi: 10.1093/neuonc/now060
pubmed: 27106404
pmcid: 5063513
Silva CB, Ongaratti BR, Trott G, Haag T, Ferreira NP, Leaes CG, Pereira-Lima JF, Oliveira Mda C (2015) Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance. Int J Clin Exp Pathol 8:13185–13192
pubmed: 26722517
pmcid: 4680462
Theodoropoulou M, Stalla GK (2013) Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 34:228–252. https://doi.org/10.1016/j.yfrne.2013.07.005
doi: 10.1016/j.yfrne.2013.07.005
pubmed: 23872332
van der Zwan WA, Bodei L, Mueller-Brand J, de Herder WW, Kvols LK, Kwekkeboom DJ (2015) GEPNETs update: radionuclide therapy in neuroendocrine tumors. Eur J Endocrinol 172:R1-8. https://doi.org/10.1530/EJE-14-0488
doi: 10.1530/EJE-14-0488
pubmed: 25117465
Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Burggasser G, Andreae F, Kurtaran A, Dudczak R (2002) Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des 8:1781–1807. https://doi.org/10.2174/1381612023393756
doi: 10.2174/1381612023393756
pubmed: 12171531